FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Ann Oncol
; 32(5): 609-619, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-33610734
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Esophageal Neoplasms
/
Adenocarcinoma
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Humans
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2021
Type:
Article